Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

4(57.1%)

Phase 1

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 4(4)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07346027Phase 1Not Yet Recruiting

Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects

Role: collaborator

NCT07324434Phase 1Enrolling By Invitation

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects

Role: collaborator

NCT04202068Phase 4Completed

A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

Role: lead

NCT01426191Completed

Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Role: lead

NCT04066621Phase 4Completed

PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)

Role: lead

NCT01760109Phase 4Completed

Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

Role: lead

NCT01601093Phase 2Suspended

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Role: lead

NCT01897831Phase 4Unknown

Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Role: lead

All 8 trials loaded